## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

	MODIFIED PTO/SB/08a (09-08)
Application Number	10/594,127
Filing Date	September 25, 2006
First Named Inventor	Akio SUGIHARA
Art Unit	1625
Examiner Name	Niloofar RAHMANI
Attorney Docket Number	Q97391

U.S. PATENTS						
Examiner Initials*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1					

	U.S. PATENT APPLICATION PUBLICATIONS						
Examiner Initials* Cite No Publication Number Kind Code Publication (			Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1						

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	1 714 965	EP	A1	2006-10-25	Astellas Pharma Inc.		
	2	1 726 304	EP	A1	2006-11-29	Astellas Pharma Inc.		

	NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials* Cite No (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.						
	1	MEALY N., et al., "Treatment of Urinary Incontinence Muscarinic M3 Antagonist", Drugs of the Future, PROUS SCIENCE, Vol. 24, No. 8, January 1, 1999, pages 871-874, XP001061585.				
	2	HEDGE Sharath S., "Antimuscarinics for the treatment of overactive bladder: Current options and emerging therapies", Current Opinion in Investigational Drugs, Vol. 5, No. 1, January 1, 2004, pages 40- 49, XP008061336.				
	3	"VESIcare", www.rxlist.com/vesicare-drug.htm, page 1, XP002500528. (2005)				
	4	*Amorphous Solids: Implications for Solubility and Stability", www.ssci- inc.com/information/RecentPublications/ApplicationNotes/Amorphous SolidsImplications/tabid/142/Default. aspx, 2003, pages 1-3, XPO025005273.				
	5	Supplementary European Search Report dated November 10, 2008				

EXAMINER SIGNATURE					
Examiner Signature	/Niloofar Rahmani/	Date Considered	01/14/2009		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

<sup>\*</sup>EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST3). 3 For Japanese patent documents, the indication of the year of the region of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.